IL1A and cryopyrin-associated periodic syndrome: While specific drugs are under development to directly inhibit NLRP3, treatments for CAPS (as for other autoinflammatory syndromes) are currently focused on IL-1 inhibitors: anakinra (the first anti-IL-1 drug clinically available), a recombinant form of IL-1RA which binds IL-1 receptor preventing both IL-1α and IL-1β binding and signaling, and canakinumab, a monoclonal antibody that selectively blocks IL-1β.